3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Lymphoid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Gliosarcoma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
53
Bevacizumab
33
Radiotherapy
27
Radiation
12
Erlotinib Hydrochloride
12
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Irinotecan
6
Vorinostat
5
Sorafenib
5
Sirolimus
5
temsirolimus
4
Magnetic Resonance Spectroscopy
4
Immunoglobulin G
4
Disulfides
4
Carmustine
4
veliparib
3
plerixafor
3
carmustine, poliferprosan 20 drug combination
3
Radiosurgery
3
Everolimus
3
Dasatinib
3
Bortezomib
3
vandetanib
2
tandutinib
2
sargramostim
2
poly ICLC
2
pembrolizumab
2
pazopanib
2
ferric pyrophosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gliosarcoma
×
Immunotherapy, Adoptive
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts